Genomic Grade Index predicts postoperative clinical outcome of GIST

British Journal of Cancer

Volumn 107, Issue 8, 2012, Pages 1433-1441

  Bertucci, F ^a,b   Finetti, P ^a   Ostrowski, J ^c   Kim, W K ^d   Kim, H ^d   Pantaleo, M A ^e   Astolfi, A ^f   Polkowski, M ^g   Birnbaum, D ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Yonsei University College of Medicine   (South Korea)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

DNA microarray; Gene expression; GIST; Imatinib; Profiling; Prognosis

Indexed keywords

IMATINIB;

16 KINASE SIGNATURE; ADULT; AGED; ARTICLE; COMPLEXITY INDEX IN SARCOMA SIGNATURE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMIC GRADE INDEX; HUMAN; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERFORMANCE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; UNIVARIATE ANALYSIS;

ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERAZINES; PROGNOSIS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84867399406     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.390     Document Type: Article

References (50)

1. Allander SV, Nupponen NN, Ringner M, Hostetter G, Maher GW, Goldberger N, Chen Y, Carpten J, Elkahloun AG, Meltzer PS (2001) Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 61: 8624-8628 (Pubitemid 34013866)
2. Antonescu CR (2011) The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 223: 251-261
3. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, Maki RG, Socci ND, DeMatteo RP, Besmer P (2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10: 3282-3290 (Pubitemid 38685432)
4. Arne G, Kristiansson E, Nerman O, Kindblom LG, Ahlman H, Nilsson B, Nilsson O (2011) Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer 129: 1149-1161
5. Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu A, Saponara M, Lolli C, Di Scioscio V, Formica S, Biasco G (2010) A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest 90: 1285-1294
6. Bertucci F, Finetti P, Cervera N, Maraninchi D, Viens P, Birnbaum D (2006) Gene expression profiling and clinical outcome in breast cancer. Omics 10: 429-443 (Pubitemid 46174577)
7. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048 (Pubitemid 44325930)
8. Casali PG, Blay JY (2010) Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): v98-102
9. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL (2010) ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467: 849-853
10. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, Terrier P, Bonvalot S, Le Cesne A, Vince-Ranchere D, Blay JY, Collin F, Guillou L, Leroux A, Coindre JM, Aurias A (2010) Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 16: 781-787
11. Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11: 865-878
12. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097-1104
13. Dematteo RP, Gold JS, Saran L, Gonen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112: 608-615 (Pubitemid 351186201)
14. Dorn J, Spatz H, Schmieder M, Barth TF, Blatz A, Henne-Bruns D, Knippschild U, Kramer K (2010) Cyclin H expression is increased in GIST with very-high risk of malignancy. BMC Cancer 10: 350
15. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868 (Pubitemid 29003722)
16. Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M, Jacquemier J, Viens P, Birnbaum D, Bertucci F (2008) Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res 68: 767-776 (Pubitemid 351206753)
17. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459-465 (Pubitemid 34747864)
18. Fujita A, Yamamoto H, Imamura M, Nakamura N, Maehara Y, Tsuneyoshi M, Oda Y (2012) Expression level of the mitotic checkpoint protein and G2-M cell cycle regulators and prognosis in gastrointestinal stromal tumors in the stomach. Virchows Arch 460: 163-169
19. Gold JS, Gonen M, Gutierrez A, Broto JM, Garcia-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 10: 1045-1052
20. Haller F, Gunawan B, von Heydebreck A, Schwager S, Schulten HJ, Wolf-Salgo J, Langer C, Ramadori G, Sultmann H, Fuzesi L (2005) Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 11: 6589-6597 (Pubitemid 41338999)
21. Haller F, Lobke C, Ruschhaupt M, Cameron S, Schulten HJ, Schwager S, von Heydebreck A, Gunawan B, Langer C, Ramadori G, Sultmann H, Poustka A, Korf U, Fuzesi L (2008a) Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). J Pathol 215: 253-262 (Pubitemid 351956706)
22. Haller F, Lobke C, Ruschhaupt M, Schulten HJ, Schwager S, Gunawan B, Armbrust T, Langer C, Ramadori G, Sultmann H, Poustka A, Korf U, Fuzesi L (2008b) Increased KIT signalling with up-regulation of cyclin D correlates to accelerated proliferation and shorter disease-free survival in gastrointestinal stromal tumours (GISTs) with KIT exon 11 deletions. J Pathol 216: 225-235
23. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD (2008a) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26: 5352-5359
24. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA (2008b) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26: 5360-5367
25. Imamura M, Yamamoto H, Nakamura N, Oda Y, Yao T, Kakeji Y Baba H, Maehara Y, Tsuneyoshi M (2007) Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol 20: 529-537 (Pubitemid 46631995)
26. Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39: 1411-1419
27. Joensuu H, Dematteo RP (2012) The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 63: 247-258
28. Joensuu H, Eriksson M, Hatrmann J, Sundby Hall K, Schutte J, Reichardt A, Schlemmer M, Wardelmann E, Ramadori G, Al-Batran S, Nilsson BE, Monge O, Kallio R, Sarlomo-Rikala M, Bono P, Leinonen M, Hohenberger P, Alvegard T, Reichardt P (2011) Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 29, (suppl; abstr LBA1)
29. Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P Plank L, Nilsson B, Cirilli C, Braconi C, Bordoni A, Magnusson MK, Linke Z, Sufliarsky J, Federico M, Jonasson JG, Dei Tos AP, Rutkowski P (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13: 265-274
30. Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, Kim H, Hyung WJ, Noh SH, Kim JH, Yun CO, Liu ET, Kim H (2005) Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24: 1066-1074 (Pubitemid 40313883)
31. Kitamura Y, Hirota S, Nishida T (2003) Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci 94: 315-320 (Pubitemid 36626361)
32. Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, Knuutila S, Miettinen M, El-Rifai W (2004) Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53: 235-240 (Pubitemid 38125511)
33. Lagarde P, Perot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R, Schoffski P, Aurias A, Coindre JM, Debiec-Rychter M, Chibon F (2012) Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 18: 826-838
34. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072
35. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83 (Pubitemid 44692418)
36. Okamoto Y, Sawaki A, Ito S, Nishida T, Takahashi T, Toyota M, Suzuki H, Shinomura Y, Takeuchi I, Shinjo K, An B, Ito H, Yamao K, Fujii M, Murakami H, Osada H, Kataoka H, Joh T, Sekido Y, Kondo Y (2012) Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. Gut 61: 392-401
37. Ostrowski J, Polkowski M, Paziewska A, Skrzypczak M, Goryca K, Rubel T, Kokoszynska K, Rutkowski P, Nowecki ZI, Vel Dobosz AJ, Jarosz D, Ruka W, Wyrwicz LS (2009) Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression. BMC Cancer 9: 413
38. Patel S (2011) Navigating risk stratification systems for the management of patients with GIST. Ann Surg Oncol 18: 1698-1704
39. Rink L, Skorobogatko Y, Kossenkov AV, Belinsky MG, Pajak T, Heinrich MC, Blanke CD, von Mehren M, Ochs MF, Eisenberg B, Godwin AK (2009) Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther 8: 2172-2182
40. Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay JY, Hogendoorn PC (2009) Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 15: 4191-4198
41. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, Gronchi A, Casali PG, Dei Tos AP (2011) Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with longterm follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 35: 1646-1656
42. Sabah M, Cummins R, Leader M, Kay E (2006) Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications. Hum Pathol 37: 648-655 (Pubitemid 43956544)
43. Schmieder M, Wolf S, Danner B, Stoehr S, Juchems MS, Wuerl P, Henne-Bruns D, Knippschild U, Hasel C, Kramer K (2008) p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia 10: 1154-1162
44. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, Terracciano L, Pross M, Insabato L, Di Vizio D, Iesalnieks I, Dirnhofer S, Hartmann A, Heinrich M, Miettinen M, Roessner A, Tornillo L (2005) Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 11: 638-645 (Pubitemid 40116890)
45. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272 (Pubitemid 43264710)
46. Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu KM, Leung SY, Yuen ST, Zhu S, Hernandez-Boussard T, Montgomery K, Nielsen TO, Patel RM, Goldblum JR, Heinrich MC, Fletcher JA, van de Rijn M (2004) Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 23: 7780-7790 (Pubitemid 39457028)
47. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165: 107-113 (Pubitemid 38821818)
48. Yamaguchi U, Nakayama R, Honda K, Ichikawa H, Hasegawa T, Shitashige M, Ono M, Shoji A, Sakuma T, KuwabaraH, Shimada Y, Sasako M, Shimoda T, Kawai A, Hirohashi S, Yamada T (2008) Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 26: 4100-4108
49. Yang D, Ylipaa A, Yang J, Hunt K, Pollock R, Trent J, Yli-Harja O, Shmulevich I, Nykter M, ZhangW(2010) An integrated study of aberrant gene copy number and gene expression in GIST and LMS. Technol Cancer Res Treat 9: 171-178
50. Ylipaa A, Hunt KK, Yang J, Lazar AJ, Torres KE, Lev DC, Nykter M, Pollock RE, Trent J, Zhang W (2011) Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumours. Cancer 117: 380-389